Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma

BMC Cancer

Table 1 Antitumor effectiveness of single mIL-12 gene electrotransfer alone or combined with irradiation on SA-1 sarcoma

Therapeutic group	N	DT (days; AM ± SE)*	GD (days; AM ± SE)**	Cures^†(%; n)	SC resistance^#
Control	12	1.7 ± 0.2	-	0
EP	13	4.2 ± 0.6	2.5 ± 0.6	0
dsRed	12	3.1 ± 0.3	1.3 ± 0.3	0
EGT dsRed	14	5.3 ± 0.9	3.5 ± 0.9	0
mIL-12	13	3.1 ± 0.4	1.4 ± 0.4	0
EGT mIL12	14	20.0 ± 3.0 ^‡	18.3 ± 3.0	7.1 (1/14)	0/1
IR	13	5.4 ± 0.9	3.7 ± 0.9	0
EP + IR	14	14.4 ± 4.2 ^‡	12.7 ± 4.2	0
dsRed + IR	9	5.3 ± 1.1	3.6 ± 1.1	0
EGT dsRed + IR	11	9.3 ± 1.9	7.5 ± 1.9	0
mIL-12 + IR	13	10.7 ± 1.7	8.9 ± 1.7	0
EGT mIL-12 + IR	14	32.6 ± 4.3 ^‡§	30.9 ± 4.3 ^§	21.4 (3/14)	1/3

Therapeutic groups: 10 Gy single dose irradiation (IR), electrical pulse application alone (EP) or combined with irradiation (EP + IR), intratumoral injection of plasmid DNA coding for mIL-12 or dsRed alone (mIL-12, dsRed) or combined with irradiation (mIL-12 + IR, dsRed + IR), mIL-12 or dsRed gene electrotransfer alone (EGT mIL-12, EGT dsRed) or combined with irradiation (EGT mIL-12 + IR, EGT dsRed + IR).
N - Number of all mice in the group.
* - Tumor doubling time - only mice with tumors were included in calculation.
** - Tumor growth delay - only mice with tumors were included in calculation.
^† - Cures were determined 100 days after the treatment.
^# - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.
^‡
- Statistical significant difference compared to control group (p < 0.05).
^§ - Statistical significant difference compared to IR (p < 0.05).

ISSN: 1471-2407